$DVA
DAVITA INC. Stock $dva

$dva Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000119312513429856 Filed on November 06, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q3
Revenue	$3.063B	$3.000B	$1.946B
YoY Change	23.62%	54.15%	10.7%
Cost Of Revenue	$2.128B	$2.095B	$1.327B
YoY Change	24.61%	57.85%	11.58%
Gross Profit	$935.4M	$904.3M	$618.5M
YoY Change	21.42%	46.21%	8.85%
Gross Profit Margin	30.54%	30.15%	31.78%
Selling, General & Admin	$320.0M	$306.6M	$199.3M
YoY Change	16.53%	53.84%	8.02%
% of Gross Profit	34.21%	33.9%	32.22%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$138.7M	$132.8M	$80.60M
YoY Change	26.67%	64.72%	18.88%
% of Gross Profit	14.83%	14.68%	13.03%
Operating Expenses	$459.5M	$439.4M	$279.4M
YoY Change	19.69%	57.27%	10.83%
Operating Profit	$484.2M	$377.1M	$340.9M
YoY Change	24.77%	10.62%	7.06%
Interest Expense	-$99.30M	-$99.20M	-$67.40M
YoY Change	0.51%	47.18%	15.81%
% of Operating Profit	-20.51%	-26.31%	-19.77%
Other Income/Expense, Net	$3.500M	$2.113M	$819.0K
YoY Change	250.0%	158.0%	2.38%
Pretax Income	$380.0M	$270.8M	$271.2M
YoY Change	34.68%	-0.16%	4.98%
Income Tax	$135.7M	$100.9M	$98.65M
% Of Pretax Income	35.71%	37.28%	36.37%
Net Earnings	$212.3M	$136.6M	$144.7M
YoY Change	36.22%	-5.59%	6.91%
Net Earnings / Revenue	6.93%	4.55%	7.44%
Basic Earnings Per Share	$1.01	$0.65	$0.76
Diluted Earnings Per Share	$0.99	$0.64	$0.75
COMMON SHARES
Basic Shares Outstanding	212.7M shares	210.4M shares	190.0M shares
Diluted Shares Outstanding		214.9M shares	193.3M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$971.3M	$977.0M	$388.0M
YoY Change	79.53%	151.8%	-31.45%
Cash & Equivalents	$946.2M	$970.7M	$382.2M
Short-Term Investments	$25.02M	$7.000M	$6.000M
Other Short-Term Assets	$176.4M	$156.9M	$46.99M
YoY Change	-12.48%	233.99%	-85.5%
Inventory	$88.81M	$84.90M	$78.32M
Prepaid Expenses	$93.88M
Receivables	$1.485B	$1.404B	$1.248B
Other Receivables	$349.1M	$360.0M	$241.0M
Total Short-Term Assets	$3.472B	$3.381B	$2.326B
YoY Change	20.27%	45.39%	-1.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.189B	$2.048B	$1.655B
YoY Change	16.93%	23.79%	23.85%
Goodwill	$9.213B	$9.144B	$5.325B
YoY Change	2.91%	71.72%
Intangibles	$2.024B	$2.060B	$177.5M
YoY Change	-4.87%	1060.05%
Long-Term Investments	$120.0M	$114.0M	$42.00M
YoY Change	27.66%	171.43%	7.69%
Other Assets	$79.60M	$79.83M	$30.56M
YoY Change	-0.32%	161.25%	-4.51%
Total Long-Term Assets	$13.63B	$13.45B	$8.498B
YoY Change	3.8%	58.22%	34.11%
TOTAL ASSETS
Total Short-Term Assets	$3.472B	$3.381B	$2.326B
Total Long-Term Assets	$13.63B	$13.45B	$8.498B
Total Assets	$17.10B	$16.83B	$10.82B
YoY Change	6.77%	55.46%	24.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$435.5M	$358.4M	$272.6M
YoY Change	5.15%	31.46%	5.26%
Accrued Expenses	$772.0M	$685.0M	$529.0M
YoY Change	36.16%	29.49%	14.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$274.7M	$260.0M	$117.8M
YoY Change	20.48%	120.67%	43.68%
Total Short-Term Liabilities	$2.462B	$2.453B	$1.337B
YoY Change	22.1%	83.5%	10.85%
LONG-TERM LIABILITIES
Long-Term Debt	$8.141B	$8.181B	$5.621B
YoY Change	-2.23%	45.55%	27.25%
Other Long-Term Liabilities	$380.3M	$353.7M	$145.2M
YoY Change	-14.29%	143.53%	-6.89%
Total Long-Term Liabilities	$380.3M	$353.7M	$5.766B
YoY Change	-14.29%	-93.87%	26.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.462B	$2.453B	$1.337B
Total Long-Term Liabilities	$380.3M	$353.7M	$5.766B
Total Liabilities	$11.80B	$11.77B	$7.604B
YoY Change	2.42%	54.78%	13.37%
SHAREHOLDERS EQUITY
Retained Earnings	$3.364B	$3.152B	$3.576B
YoY Change	-9.86%	-11.86%
Common Stock	$213.0K	$213.0K	$135.0K
YoY Change	-21.11%	57.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$1.564B
YoY Change
Treasury Stock Shares	0.000 shares		39.52M shares
Shareholders Equity	$4.432B	$4.268B	$2.537B
YoY Change
Total Liabilities & Shareholders Equity	$17.10B	$16.83B	$10.82B
YoY Change	6.77%	55.46%	24.32%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	$212.3M	$136.6M	$144.7M
YoY Change	36.22%	-5.59%	6.91%
Depreciation, Depletion And Amortization	$138.7M	$132.8M	$80.60M
YoY Change	26.67%	64.72%	18.88%
Cash From Operating Activities	$354.1M	$733.2M	$366.6M
YoY Change	76.87%	100.0%	-25.97%
INVESTING ACTIVITIES
Capital Expenditures	-$218.1M	-$141.1M	-$128.4M
YoY Change	27.39%	9.89%	32.37%
Acquisitions
YoY Change
Other Investing Activities	-$81.70M	-$88.10M	-$71.10M
YoY Change	-97.89%	23.91%	-90.23%
Cash From Investing Activities	-$299.8M	-$229.2M	-$199.6M
YoY Change	-92.59%	14.83%	-75.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-78.80M	-150.5M	-58.50M
YoY Change	-101.97%	157.26%	-141.61%
NET CHANGE
Cash From Operating Activities	354.1M	733.2M	366.6M
Cash From Investing Activities	-299.8M	-229.2M	-199.6M
Cash From Financing Activities	-78.80M	-150.5M	-58.50M
Net Change In Cash	-24.50M	353.5M	108.5M
YoY Change	-116.08%	225.81%	-157.53%
FREE CASH FLOW
Cash From Operating Activities	$354.1M	$733.2M	$366.6M
Capital Expenditures	-$218.1M	-$141.1M	-$128.4M
Free Cash Flow	$572.2M	$874.3M	$495.0M
YoY Change	54.07%	76.63%	-16.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2453126000
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	212700000	shares
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	382194000
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	212671800	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q3	us-gaap	Longterm Debt Weighted Average Interest Rate LongtermDebtWeightedAverageInterestRate	0.0486	pure
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	212671800	shares
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	1895122000
CY2013Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Liabilities VariableInterestEntityConsolidatedCarryingAmountLiabilities	311949000
CY2013Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	34947000
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4214000
CY2013Q3	us-gaap	Senior Notes SeniorNotes	2800000000
CY2013Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	61151000
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	685352000
CY2013Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	4437431000
CY2013Q3	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1699441000
CY2013Q3	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	26204000
CY2013Q3	us-gaap	Other Commitment OtherCommitment	2000000
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1120276000
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	358402000
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	353723000
CY2013Q3	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	259770000
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	4267986000
CY2013Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	10722000
CY2013Q3	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	350000000
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3151711000
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	843928000
CY2013Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8459843000
CY2013Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	221602000
CY2013Q3	us-gaap	Minority Interest MinorityInterest	169445000
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	908124000
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	267108000
CY2013Q3	us-gaap	Capital Lease Obligations CapitalLeaseObligations	138198000
CY2013Q3	us-gaap	Liabilities Liabilities	11768656000
CY2013Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	621232000
CY2013Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	60943000
CY2013Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	481840000
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	213000
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16827319000
CY2013Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	769713000
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79833000
CY2013Q3	us-gaap	Goodwill Goodwill	9144242000
CY2013Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	64351000
CY2013Q3	us-gaap	Investments Investments	25754000
CY2013Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2059568000
CY2013Q3	us-gaap	Other Long Term Investments OtherLongTermInvestments	18958000
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1404050000
CY2013Q3	us-gaap	Inventory Net InventoryNet	84899000
CY2013Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	398138000
CY2013Q3	us-gaap	Variable Interest Entity Consolidated Carrying Amount Assets VariableInterestEntityConsolidatedCarryingAmountAssets	476813000
CY2013Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	193866000
CY2013Q3	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	41465000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2048235000
CY2013Q3	us-gaap	Assets Assets	16827319000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	970694000
CY2013Q3	us-gaap	Short Term Investments ShortTermInvestments	6796000
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	156940000
CY2013Q3	us-gaap	Other Receivables OtherReceivables	295540000
CY2013Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	104293000
CY2013Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	18639000
CY2013Q3	us-gaap	Long Term Investments LongTermInvestments	72568000
CY2013Q3	us-gaap	Assets Current AssetsCurrent	3381408000
CY2013Q3	dva	Medical Expense Payable MedicalExpensePayable	270762000
CY2013Q3	dva	Long Term Debt Maturities Repayments Of Principal In Year Six LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix	804715000
CY2013Q3	dva	Accounts Receivable Months Outstanding AccountsReceivableMonthsOutstanding	P4M
CY2013Q3	dva	Line Of Credit Weighted Average Interest Rate LineOfCreditWeightedAverageInterestRate	0.0418	pure
CY2013Q3	dva	Long Term Debt And Capital Lease Obligations Noncurrent LongTermDebtAndCapitalLeaseObligationsNoncurrent	8181434000
CY2013Q3	dva	Business Acquisition Contingent Earn Out Fair Value Disclosure BusinessAcquisitionContingentEarnOutFairValueDisclosure	25628000
CY2013Q3	dva	Long Term Debt Maturities Repayments Of Principal In Year Seven And Thereafter LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSevenAndThereafter	3679903000
CY2013Q3	dva	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	438611000
CY2013Q3	dva	Legal Loss Contingency LegalLossContingency	397000000
CY2013Q3	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	57770000
CY2013Q3	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	20158000
CY2013Q3	dva	Percentage Of Outstanding Patient Accounts Receivables PercentageOfOutstandingPatientAccountsReceivables	1.00	pure
CY2013Q3	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	10660000
CY2013Q3	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	5596000
CY2013Q3	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	1006664000
CY2013Q3	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9315530000
CY2013Q3	dva	Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments	4227000
CY2013Q3	dva	Carrying Amount Of Longterm Debt Net Of Unamortized Discount Or Premium Current And Noncurrent CarryingAmountOfLongtermDebtNetOfUnamortizedDiscountOrPremiumCurrentAndNoncurrent	8441204000
CY2011Q4	us-gaap	Goodwill Goodwill	4946976000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393752000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	269724566	shares
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	58727416	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	210997150	shares
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2016425000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15297000
CY2012Q4	us-gaap	Senior Notes SeniorNotes	2800000000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	67546000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	566911000
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3916925000
CY2012Q4	us-gaap	Property Plant And Equipment Owned Accumulated Depreciation PropertyPlantAndEquipmentOwnedAccumulatedDepreciation	1522183000
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1208665000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	414143000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	443743000
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	227791000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	3763137000
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	12073000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	3731835000
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	8575870000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	245122000
CY2012Q4	us-gaap	Minority Interest MinorityInterest	153788000
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	96594000
CY2012Q4	us-gaap	Liabilities Liabilities	11511997000
CY2012Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Noncontrolling Interest TemporaryEquityCarryingAmountAttributableToNoncontrollingInterest	580692000
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	568616000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	270000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16009614000
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	710638000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	79854000
CY2012Q4	us-gaap	Goodwill Goodwill	8952987000
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	55454000
CY2012Q4	us-gaap	Investments Investments	21123000
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2128118000
CY2012Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	13985000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1424303000
CY2012Q4	us-gaap	Inventory Net InventoryNet	78126000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	315782000
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1162336000
CY2012Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	174345000
CY2012Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	35150000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1872370000
CY2012Q4	us-gaap	Assets Assets	16009614000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	533748000
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	7138000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	201572000
CY2012Q4	us-gaap	Other Receivables OtherReceivables	265671000
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	21545000
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	59341000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2881794000
CY2012Q4	dva	Medical Expense Payable MedicalExpensePayable	238964000
CY2012Q4	dva	Long Term Debt And Capital Lease Obligations Noncurrent LongTermDebtAndCapitalLeaseObligationsNoncurrent	8326534000
CY2012Q4	dva	Accumulated Amortization Of Intangible Assets AccumulatedAmortizationOfIntangibleAssets	304323000
CY2012Q4	dva	Assets Held For Sale Goodwill AssetsHeldForSaleGoodwill	31853000
CY2012Q4	dva	Acquisition Obligations And Other Notes Payable AcquisitionObligationsAndOtherNotesPayable	64276000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214631587	shares
CY2012Q4	dva	Mutual Fund Investments At Fair Value MutualFundInvestmentsAtFairValue	15185000
CY2012Q4	dva	Alliance And Product Supply Agreement Net AllianceAndProductSupplyAgreementNet	14657000
CY2012Q4	dva	Certificates Of Deposit Money Market Funds And United States Government Securities CertificatesOfDepositMoneyMarketFundsAndUnitedStatesGovernmentSecurities	5938000
CY2012Q4	dva	Investments And Other Current Assets InvestmentsAndOtherCurrentAssets	923743000
CY2012Q4	dva	Long Term Debt And Other Noncurrent LongTermDebtAndOtherNoncurrent	9495572000
CY2012Q4	dva	Available For Sale Securities Gross Unrealized Gain Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainLossAccumulatedInInvestments	2146000
CY2012Q4	dva	Carrying Amount Of Longterm Debt Net Of Unamortized Discount Or Premium Current And Noncurrent CarryingAmountOfLongtermDebtNetOfUnamortizedDiscountOrPremiumCurrentAndNoncurrent	8554325000
	dei	Trading Symbol TradingSymbol	DVA
	dei	Entity Registrant Name EntityRegistrantName	DAVITA HEALTHCARE PARTNERS INC.
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000927066
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.01
	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-1340000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.96
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2713000	shares
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-6395000
	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.0487	pure
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1419154000
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.95
	us-gaap	Significant Supply Commitment Description SignificantSupplyCommitmentDescription	Certain consolidated joint ventures are contractually scheduled to dissolve after terms ranging from ten to fifty years.
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.90
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	-23520000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3871000	shares
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y3M18D
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	209725439	shares
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	474000
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	26239000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	399527000
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	13375000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	234802000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1367000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1034000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	13249000
	us-gaap	Business Combination Consideration Transferred Liabilities Incurred BusinessCombinationConsiderationTransferredLiabilitiesIncurred	11795000
	us-gaap	Profit Loss ProfitLoss	512928000
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	Segment
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>7. Contingencies</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The majority of the Company’s revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient’s medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company’s revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.</font></p> <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"> <font style="font-family:Times New Roman" size="2"><b><i>Inquiries by the Federal Government and Certain Related Civil Proceedings</i></b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Vainer Private Civil Suit:</u> In December 2008, the Company received a subpoena for documents from the OIG relating to the pharmaceutical products Zemplar, Hectorol, Venofer, Ferrlecit and EPO, as well as other related matters. The subpoena covered the period from January 2003 to December 2008. The Company has been in contact with the U.S. Attorney’s Office for the Northern District of Georgia and the U.S. Department of Justice in Washington, DC since November 2008 relating to this matter, and has been advised that this was a civil inquiry. On June 17, 2009, the Company learned that the allegations underlying this inquiry were made as part of a civil complaint filed by individuals and brought pursuant to the <i>qui tam</i> provisions of the federal False Claims Act. On April 1, 2011, the U.S. District Court for the Northern District of Georgia ordered the case to be unsealed. At that time, the Department of Justice and U.S. Attorney’s Office filed a notice of declination stating that the U.S. would not be intervening and not pursuing the relators’ allegation in litigation. On July 25, 2011, the relators, Daniel Barbir and Dr. Alon Vainer, filed their amended complaint in the U.S. District Court for the Northern District of Georgia, purportedly on behalf of the federal government. The allegations in the complaint relate to the Company’s drug administration practices for the Company’s dialysis operations for Vitamin D and iron agents for a period from 2003 through 2010. The complaint seeks monetary damages and civil penalties as well as costs and expenses. The Company is vigorously defending this matter and intends to continue to do so. The Company can make no assurances as to the time or resources that will be needed to devote to this litigation or its final outcome.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>2010 U.S. Attorney Physician Relationship Investigation</u>: In May 2010, the Company received a subpoena from the OIG’s office in Dallas, Texas. The civil subpoena covers the period from January 2005 to May 2010, and seeks production of a wide range of documents relating to the Company’s dialysis operations, including documents related to, among other things, financial relationships with physicians and joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute and the False Claims Act. The Company has been advised by the attorneys conducting this civil investigation that they believe that some or all of the Company’s joint ventures do not comply with the anti-kickback statute and the False Claims Act. The Company disagrees that its joint venture structure generally, which the Company believes is widely used in the dialysis industry and other segments of the healthcare industry substantially in the form that the Company uses it, violates the federal anti-kickback statute or the False Claims Act. As to individual transactions, the Company made significant effort to ensure that its joint venture structures and process complied with the rules, but the Company is talking with the government about addressing its concerns. The focus of this investigation overlaps substantially with the 2011 U.S. Attorney Physician Relationship Investigation described below. The Company is engaged in good faith discussions with the attorneys from the United States Attorney’s Office for the District of Colorado, the Civil Division of the United States Department of Justice and the Office of the Inspector General in an effort to find a mutually acceptable resolution to this matter and the 2011 U.S. Attorney Physician Relationship Investigation. Discussions have advanced to a point where the Company believed it was appropriate to accrue an estimated loss contingency reserve of $300,000 in the first quarter of 2013 and an additional $97,000 in the third quarter of 2013 in connection with offers to settle the related civil, administrative and criminal matters. However, the discussions are ongoing, and until concluded, there can be no certainty about the timing or likelihood of a definitive resolution or the scope of any potential restrictions or impact on future operations that may be agreed upon in connection with a settlement. As these discussions proceed and additional information becomes available to us, the amount of the estimated loss contingency reserve may need to be adjusted further to reflect this new information. This matter will continue to require management’s attention and significant legal expense, and the Company can make no assurances as to the final outcome.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>2011 U.S. Attorney Physician Relationship Investigation</u>: In August 2011, the Company announced it had learned that the U.S. Attorney’s Office for the District of Colorado would be investigating certain activities of its dialysis business in connection with information being provided to a grand jury. This investigation relates to the Company’s relationships with physicians, including its joint ventures, and whether those relationships and joint ventures comply with the federal anti-kickback statute, and overlaps substantially with the 2010 U.S. Attorney Physician Relationship Investigation described above. The Company has received a number of subpoenas for documents covering the period from January 2006 to November 2012, and the Company has produced documents in response to those subpoenas and other requests. In addition, certain current and former members of the Board, executives and other teammates have received subpoenas to testify before the grand jury. It is possible that criminal proceedings may be initiated against the Company in connection with this investigation. As noted above, the Company is engaged in good faith discussions in an effort to find a mutually acceptable resolution of both this matter and the 2010 U.S. Attorney Physician Relationship Investigation. As also noted above, the discussions are ongoing, and until concluded, there can be no certainty about the timing or likelihood of a definitive resolution, or the scope of any potential restrictions or impact on future operations that may be agreed upon in connection with a settlement. This matter will continue to require management’s attention and significant legal expense, and the Company can make no assurances as to the final outcome.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>2011 U.S. Attorney Medicaid Investigation:</u> In October 2011, the Company announced that it would be receiving a request for documents, which could include an administrative subpoena from the Office of Inspector General for the U.S. Department of Health and Human Services. Subsequent to the Company’s announcement of this 2011 U.S. Attorney Medicaid Investigation, the Company received a request for documents in connection with the inquiry by the U.S. Attorney’s Office for the Eastern District of New York. The request relates to payments for infusion drugs covered by Medicaid composite payments for dialysis. The Company believes this inquiry is civil in nature. The Company does not know the time period or scope. The Company understands that certain other providers that operate dialysis clinics in New York may be receiving or have received a similar request for documents. The Company is cooperating with the government and is producing the requested documents.</font></p> <p style="font-size:1px;margin-top:12px;margin-bottom:0px">  </p> <p style="margin-top:0px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Swoben Private Civil Suit</u>: In April 2013, the Company’s HealthCare Partners (HCP) subsidiary was served with a civil complaint filed by a former employee of SCAN Health Plan (SCAN), a health maintenance organization (HMO). On July 13, 2009, pursuant to the <i>qui tam</i> provisions of the federal False Claims Act and the California False Claims Act, James M. Swoben, as relator, filed a <i>qui tam</i> action in the United States District Court for the Central District of California purportedly on behalf of the United States of America and the State of California against SCAN, and certain other defendants whose identities were under seal. The allegations in the complaint relate to alleged overpayments received from government healthcare programs. In or about August 2012, SCAN entered into a settlement agreement with the United States of America and the State of California. The United States and the State of California partially intervened in the action for the purpose of settlement with and dismissal of the action against SCAN. In or about November 2011, the relator filed his Third Amended Complaint under seal alleging violations of the federal False Claims Act and the California False Claims Act, which named additional defendants, including HCP and certain health insurance companies (the defendant HMOs). The allegations in the complaint against HCP relate to patient diagnosis coding to determine reimbursement in the Medicare Advantage program, referred to as Hierarchical Condition Coding (HCC) and Risk Adjustment Factor (RAF) scores. The complaint sought monetary damages and civil penalties as well as costs and expenses. The United States Department of Justice reviewed these allegations and in January 2013 declined to intervene in the case. On June 26, 2013, HCP and the defendant HMOs filed their respective motions to dismiss the Third Amended Complaint pursuant to Federal Rules of Civil Procedure 12(b)(6) and 9(b), challenging the legal sufficiency of the claims asserted in the complaint. On July 30, 2013, the court granted HCP’s motion and dismissed with prejudice all of the claims in the Third Amended Complaint and judgment was entered in September 2013. The court specifically determined that further amendments to the complaint would be futile because, in part, the allegations were publicly disclosed in reports and other sources relating to audits conducted by the Centers of Medicare & Medicaid Services. In October 2013, the plaintiff appealed to the United States Court of Appeals for the Ninth Circuit and the court’s disposition of the appeal is pending.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Except for the private civil complaints filed by the relators as described above, to the Company’s knowledge, no proceedings have been initiated against the Company at this time in connection with any of the inquiries by the federal government. Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved, it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and on-going discussions with regulators. Responding to the subpoenas or inquiries and defending the Company in the relator proceedings will continue to require management’s attention and significant legal expense. Any negative findings in the inquiries or relator proceedings could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs and, to the extent criminal proceedings may be initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of these inquiries, or the potential outcome of the relators’ claims (except as described above), or the potential range of damages, if any.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Haverhill Retirement System Shareholder Derivative Civil Suit</u>: On May 17, 2013, Haverhill Retirement System (Haverhill), a shareholder of the Company, filed a shareholder derivative lawsuit in the U.S. District Court for the District of Colorado against the directors of the Company and against the Company, as nominal defendant. The complaint alleges, among other things, that the Company’s directors breached fiduciary duties to the Company relating to the inquiries by the federal government described above, the Vainer <i>qui tam</i> private civil suit described above and the Woodard <i>qui tam</i> private civil suit for which the Company previously announced a settlement in July 2012. No response by the Company or the directors is required in this action until the court determines certain preliminary procedural matters that are pending. (See description of the Clark matter below for a description of how the Haverhill and Clark civil suits are related and certain pending procedural matters that will determine whether these cases will proceed separately or on a consolidated basis.)</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2"><u>Clark Shareholder Derivative Civil Suit</u>: As we previously disclosed, on August 7, 2012, a shareholder derivative lawsuit was filed in the U.S. District Court for the District of Colorado against certain of our current and former directors and executives and against the Company, as nominal defendant. The complaint alleged, among other things, that such officers and directors breached fiduciary duties to the Company relating to substantially the same matters that are now the subject of the Haverhill shareholder derivative civil suit described above. As we also previously disclosed, on October 19, 2012, the court ordered that the Clark case be administratively closed, subject to being reopened upon a showing of good cause by any party. Subsequent to the filing of the Haverhill derivative civil suit described above, Haverhill filed a motion seeking to consolidate the Clark civil suit with the Haverhill civil suit and to be appointed lead plaintiff. Clark has opposed the motion and, upon request of the parties, the court has reopened the Clark case. Clark has filed an amended complaint and its own motion to be named lead plaintiff if the Haverhill and Clark civil suits are consolidated. The outcome of these procedural matters is pending, and after the court enters its ruling, the Company will be required to respond to the allegations in either a consolidated action or separate actions.</font></p> <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"> <font style="font-family:Times New Roman" size="2"><i>Other</i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company has received several notices of claims from commercial payors and other third parties related to historical billing practices and claims against DVA Renal Healthcare (formerly known as Gambro Healthcare), a subsidiary of the Company, related to historical Gambro Healthcare billing practices and other matters covered by its 2004 settlement agreement with the Department of Justice and certain agencies of the U.S. government. The Company has received no further indication that any of these claims are active, and some of them may be barred by applicable statutes of limitations. To the extent any of these claims might proceed, the Company intends to defend against them vigorously; however, the Company may not be successful and these claims may lead to litigation and any such litigation may be resolved unfavorably. At this time, the Company cannot predict the ultimate outcome of these matters or the potential range of damages, if any.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">A wage and hour claim, which has been styled as a class action, is pending against the Company in the Superior Court of California. The Company was served with the complaint in this lawsuit in April 2008, and it has been amended since that time. The complaint, as amended, alleges that the Company failed to provide meal periods, failed to pay compensation in lieu of providing rest or meal periods, failed to pay overtime, and failed to comply with certain other California Labor Code requirements. In September 2011, the court denied the plaintiffs’ motion for class certification. Plaintiffs appealed that decision. In January 2013, the Court of Appeals affirmed the trial court’s decision on some claims, but remanded the case to the trial court for clarification of its decision on one of the claims. The Company has reached an agreement with the plaintiffs to settle the claim that was remanded to the trial court, and the court has preliminarily approved that settlement. The amount of the settlement is not material to the Company’s condensed consolidated financial statements. The Company intends to continue to vigorously defend against these claims. Any potential settlement of the remaining claims is not anticipated to be material to the Company’s consolidated financial statements.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">In October 2007, the Company was contacted by the Attorney General’s Office for the State of Nevada. The Attorney General’s Office informed the Company that it was conducting a civil and criminal investigation of the Company’s operations in Nevada and that the investigation related to the billing of pharmaceuticals by the Company’s dialysis business, including EPO. In February 2008, the Attorney General’s Office informed the Company that the civil and criminal investigation had been discontinued. The Attorney General’s Office further advised the Company that Nevada Medicaid intended to conduct audits of end stage renal disease (ESRD) dialysis providers in Nevada and that such audits would relate to the issues that were the subject of the investigation. To the Company’s knowledge, no court proceedings have been initiated against the Company at this time. Any negative audit findings could result in a substantial repayment by the Company. At this time, the Company cannot predict the ultimate outcome of this matter or the potential range of damages, if any.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">In addition to the foregoing, the Company is subject to claims and suits, including from time to time, contractual disputes and professional and general liability claims, as well as audits and investigations by various government entities, in the ordinary course of business. The Company believes that the ultimate resolution of any such pending proceedings, whether the underlying claims are covered by insurance or not, will not have a material adverse effect on its financial condition, results of operations or cash flows.</font></p> </div>
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-139000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	524011000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	6630000
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	234802000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	421168000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	13236000
	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	2728000
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8700841000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1337000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	31722000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	1583000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	421168000
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	99736000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	744958000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1206000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-20856000
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	50326174000
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	542390000
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	5938498000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	432251000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17861000
	us-gaap	Operating Income Loss OperatingIncomeLoss	1065955000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	53000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	2236000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	407919000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	499692000
	us-gaap	Net Income Loss NetIncomeLoss	421168000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5494000
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	6155223000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	11083000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	17466000
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-56977000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-52085000
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	192822000
	us-gaap	Costs And Expenses CostsAndExpenses	7634886000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-19922000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	91760000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	114877000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	857658000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-404223000
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	40870000
	us-gaap	Share Based Compensation ShareBasedCompensation	47095000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3636000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	389263000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	906226000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	436946000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	1376000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	1091000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	155000
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	397000000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	245266000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-899000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	62282000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-9433000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-15212000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-71581000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	51757000
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	6083000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12432000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	49941883000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	31722000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	91503000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-577086000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	94000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	91760000
	dva	Patient Care Costs PatientCareCosts	6070545000
	dva	Health Care Partners Capitation Revenue HealthCarePartnersCapitationRevenue	2219953000
	dva	Income Loss From Discontinued Operations Per Basic Share IncomeLossFromDiscontinuedOperationsPerBasicShare	0.06
	dva	Debt Expense DebtExpense	322334000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	407919000
	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	216725000
	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	322334000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	211914000	shares
	dva	Goodwill Other GoodwillOther	1161000
	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	5000	shares
	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	209725000	shares
	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	419828000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	407919000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	48173000
	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	214632000	shares
	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	-54203000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	5039000
	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	211000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-1074000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	389387000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	35757000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	-384301000
	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	30041000
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.02
	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-10765000
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.98
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	192248452	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3630000	shares
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	900613000
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	2.01
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.98
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3282000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188618198	shares
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8314000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	378949000
	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	419114000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1387000
	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	5257000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	225000
	us-gaap	Profit Loss ProfitLoss	457437000
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	238000
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	458638000
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	3452000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	380178000
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	238000
	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	5708427000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2698000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	39346000
	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-6104000
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	380178000
	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	81978000
	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	13774000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	719142000
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1593000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	51349000
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	25821996000
	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	408701000
	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	5254832000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	381379000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-3429000
	us-gaap	Operating Income Loss OperatingIncomeLoss	909028000
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1276000
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	379953000
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	457199000
	us-gaap	Net Income Loss NetIncomeLoss	380178000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1958000
	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	5422100000
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1201000
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	12992000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1374000
	us-gaap	Costs And Expenses CostsAndExpenses	4799399000
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-1295555000
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	77259000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	113101000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	616106000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-125457000
	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	60252000
	us-gaap	Share Based Compensation ShareBasedCompensation	34857000
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3534000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	232691000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	443176000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-11558000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	12375000
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	6796000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	124000
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	79292000
	us-gaap	Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options EmployeeServiceShareBasedCompensationCashReceivedFromExerciseOfStockOptions	2174000
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1268767000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	261943000
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	43000
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	2118000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-7586000
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-69108000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-18200000
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	5064000
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	1844000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8395000
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	26992105000
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	39346000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	87223000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-786757000
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	75000
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	77259000
	dva	Patient Care Costs PatientCareCosts	3876090000
	dva	Health Care Partners Capitation Revenue HealthCarePartnersCapitationRevenue	44894000
	dva	Income Loss From Discontinued Operations Per Basic Share IncomeLossFromDiscontinuedOperationsPerBasicShare	0.01
	dva	Debt Expense DebtExpense	192584000
	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	379953000
	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	167268000
	dva	Segment Reporting Information Acquisitions Related Transaction Expenses SegmentReportingInformationAcquisitionsRelatedTransactionExpenses	17771000
	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	192584000
	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	188612000	shares
	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	6000	shares
	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	188618000	shares
	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	379953000
	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	38848000
	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	192248000	shares
	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	369413000
	dva	Gain Loss On Disposal Of Assets And Other Noncash Charges GainLossOnDisposalOfAssetsAndOtherNoncashCharges	17244000
	dva	Payments For Proceeds From Sale Of Investments In Securities And Other PaymentsForProceedsFromSaleOfInvestmentsInSecuritiesAndOther	-9188000
	dva	Distributions From Equity Investments DistributionsFromEquityInvestments	2000
	dva	Adjustment Income Loss From Equity Method Investments AdjustmentIncomeLossFromEquityMethodInvestments	-10000
	dva	Adjustment Depreciation And Amortization AdjustmentDepreciationAndAmortization	234368000
	dva	Increase Decrease In Other Current Receivables And Other Current Assets IncreaseDecreaseInOtherCurrentReceivablesAndOtherCurrentAssets	-65047000
	dva	Proceeds From Repayments Of Long Term Debt ProceedsFromRepaymentsOfLongTermDebt	1170098000
	dva	Contribution From Noncontrolling Interest ContributionFromNoncontrollingInterest	19368000
CY2012	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	709000
CY2012	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	4051398000
CY2012	dva	Goodwill Other GoodwillOther	-843000
CY2012Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.76
CY2012Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-3089000
CY2012Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.75
CY2012Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	193269240	shares
CY2012Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3309000	shares
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.76
CY2012Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.75
CY2012Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	472000	shares
CY2012Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	189959716	shares
CY2012Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	3064000
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	445000
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-5000
CY2012Q3	us-gaap	Profit Loss ProfitLoss	172550000
CY2012Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax	-13000
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	173649000
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	144721000
CY2012Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-13000
CY2012Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	1945888000
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	819000
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-1741000
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	144721000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	271210000
CY2012Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-135000
CY2012Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	146495000
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	1783031000
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	145820000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	340885000
CY2012Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	144726000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	172563000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	144721000
CY2012Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	1842853000
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1099000
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	1605003000
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	27829000
CY2012Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	197912000
CY2012Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1390000
CY2012Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	80100000
CY2012Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	1292000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98647000
CY2012Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-2530000
CY2012Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	27829000
CY2012Q3	dva	Patient Care Costs PatientCareCosts	1327373000
CY2012Q3	dva	Health Care Partners Capitation Revenue HealthCarePartnersCapitationRevenue	16362000
CY2012Q3	dva	Debt Expense DebtExpense	70494000
CY2012Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	144726000
CY2012Q3	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	59822000
CY2012Q3	dva	Segment Reporting Information Acquisitions Related Transaction Expenses SegmentReportingInformationAcquisitionsRelatedTransactionExpenses	1335000
CY2012Q3	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	70494000
CY2012Q3	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	189954000	shares
CY2012Q3	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	6000	shares
CY2012Q3	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	189960000	shares
CY2012Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	144726000
CY2012Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	12177000
CY2012Q3	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	193269000	shares
CY2012Q3	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	141632000
CY2013Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.65
CY2013Q3	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2194000	shares
CY2013Q3	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	21000
CY2013Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.64
CY2013Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214902860	shares
CY2013Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2314000	shares
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.65
CY2013Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.64
CY2013Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4908000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	210394560	shares
CY2013Q3	us-gaap	Stock Issued During Period Shares Stock Splits StockIssuedDuringPeriodSharesStockSplits	2000	shares
CY2013Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	9223000
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	648000
CY2013Q3	us-gaap	Minority Interest Change In Redemption Value MinorityInterestChangeInRedemptionValue	259000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100930000
CY2013Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-3464000
CY2013Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	33208000
CY2013Q3	dva	Patient Care Costs PatientCareCosts	2095334000
CY2013Q3	dva	Health Care Partners Capitation Revenue HealthCarePartnersCapitationRevenue	747264000
CY2013Q3	us-gaap	Profit Loss ProfitLoss	169836000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	168956000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	136887000
CY2013Q3	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	2999586000
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2113000
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-7733000
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	136887000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	270766000
CY2013Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	2741000
CY2013Q3	us-gaap	Health Care Organization Other Revenue HealthCareOrganizationOtherRevenue	200100000
CY2013Q3	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	2052222000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	135748000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	377074000
CY2013Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	136628000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	169836000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	136628000
CY2013Q3	us-gaap	Health Care Organization Patient Service Revenue HealthCareOrganizationPatientServiceRevenue	2126699000
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-880000
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	2622512000
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	33208000
CY2013Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	305138000
CY2013Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1498000
CY2013Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	132765000
CY2013Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	97000000
CY2013Q3	dva	Debt Expense DebtExpense	108421000
CY2013Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Diluted IncomeLossFromContinuingOperationsAvailableToCommonStockholdersDiluted	136887000
CY2013Q3	dva	Provision For Doubtful Accounts On Patient Service Revenue ProvisionForDoubtfulAccountsOnPatientServiceRevenue	74477000
CY2013Q3	dva	Debt Expense And Redemption Charges DebtExpenseAndRedemptionCharges	108421000
CY2013Q3	dva	Weighted Average Number Basic Shares Outstanding Adjustment WeightedAverageNumberBasicSharesOutstandingAdjustment	212584000	shares
CY2013Q3	dva	Stock Issued Or Vested During Period Shares Stock Awards StockIssuedOrVestedDuringPeriodSharesStockAwards	5000	shares
CY2013Q3	dva	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	210395000	shares
CY2013Q3	dva	Related Party Ownership Interest In Parent Company RelatedPartyOwnershipInterestInParentCompany	0.50	pure
CY2013Q3	dva	Income Loss From Continuing Operations Available To Common Stockholders Basic IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic	136887000
CY2013Q3	dva	Segment Reporting Information Corporate Expenses SegmentReportingInformationCorporateExpenses	21267000
CY2013Q3	dva	Weighted Average Shares Outstanding Diluted WeightedAverageSharesOutstandingDiluted	214903000	shares
CY2013Q3	dva	Changes From Net Income Attributable To Parent And Transfers From To Noncontrolling Interests ChangesFromNetIncomeAttributableToParentAndTransfersFromToNoncontrollingInterests	136649000

Files In Submission

Name	View Source	Status
0001193125-13-429856-index-headers.html	Edgar Link	pending
0001193125-13-429856-index.html	Edgar Link	pending
0001193125-13-429856.txt	Edgar Link	pending
0001193125-13-429856-xbrl.zip	Edgar Link	pending
d599796d10q.htm	Edgar Link	pending
d599796dex121.htm	Edgar Link	pending
d599796dex311.htm	Edgar Link	pending
d599796dex312.htm	Edgar Link	pending
d599796dex321.htm	Edgar Link	pending
d599796dex322.htm	Edgar Link	pending
dva-20130930.xml	Edgar Link	completed
dva-20130930.xsd	Edgar Link	pending
dva-20130930_cal.xml	Edgar Link	unprocessable
dva-20130930_def.xml	Edgar Link	unprocessable
dva-20130930_lab.xml	Edgar Link	unprocessable
dva-20130930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DVA
DAVITA INC. Stock $dva

2013 Q4 Form 10-Q Financial Statement

#000119312513429856 Filed on November 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA DAVITA INC. Stock $dva

2013 Q4 Form 10-Q Financial Statement

#000119312513429856 Filed on November 06, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DVA
DAVITA INC. Stock $dva